Related Experiment Video
Updated: Sep 15, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Kushenol I combats ulcerative colitis via intestinal barrier preservation and gut microbiota optimization
Xu-Dong He1,2, Min Li1,2, Xiang-Duo Zuo1,2
1College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Kunming 650500, Yunnan Province, China.
Background:
Kushenol I (KSCI) exhibits potential anti-inflammatory and antioxidant activities. However, its therapeutic effects and mechanisms in ulcerative colitis (UC) remain unclear.
Aim:
To investigate the therapeutic effects and mechanisms of KSCI in alleviating UC.
Methods:
Therapeutic targets for KSCI in treating UC were identified using network pharmacology. Molecular docking and dynamics simulations confirmed the interactions between KSCI and these targets. In a murine UC model induced by dextran sodium sulfate (DSS), the anti-inflammatory and antioxidant effects of KSCI were evaluated following oral administration, as well as its impact on intestinal barrier function and immune response modulation. Finally, changes in gut microbiota composition were analyzed using 16S ribosomal RNA sequencing.
Results:
A total of 192 potential targets of KSCI in treating UC were identified using network pharmacology. KSCI bound stably to core targets including protein kinase B (AKT), p38 mitogen-activated protein kinase (p38 MAPK), NOD-like receptor thermal protein domain associated protein 3 (NLRP3), phosphoinositide 3-kinase (PI3K), forkhead box O1 (FOXO1), and Toll-like receptor 4 (TLR4). The oral administration of KSCI improved colon length and body weight, and reduced disease activity in a mouse model of DSS-induced UC. KSCI suppressed pro-inflammatory cytokines (interleukin [IL-1β], IL-6, IL-17, and tumor necrosis factor alpha) and promoted the expression of the anti-inflammatory cytokine IL-10. It also inhibited key signaling molecules and modulated the expression of IL-1β, AKT, p38 MAPK, NLRP3, PI3K, AKT, FOXO1, and TLR4. KSCI exhibited potent antioxidant effects, ameliorating colonic inflammation and tissue damage. It improved intestinal barrier function, influenced gut microbiota composition, and increased splenic T-cell percentages.
Conclusion:
KSCI alleviated DSS-induced UC by modulating gut microbiota, enhancing the intestinal barrier, reducing inflammation and oxidative stress, and regulating the immune response.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Constipation-Predominant IBS

